{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:21:08Z","timestamp":1788790868408,"version":"build-2803163510"},"reference-count":82,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["aspenjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Parenter Enteral Nutr"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Drug administration through feeding tubes presents many challenges to the healthcare provider. There is little information available on medications than can be delivered safely when crushed and what efforts can be implemented to minimize clogging the feeding tube. Our institution requested a comprehensive examination of all oral medications for the feeding tube route.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This report is a synopsis of the physical evaluation of 323 different oral medications for their appropriateness for feeding tube administration with distal site in either the stomach or jejunum. A worksheet was created for each medication. This document contained a review of the chemical and physical properties that would contribute to delivery of the medication. Each medication was then studied for the degree of disintegration, pH, osmolality, and potential to form clogs. For drugs that needed to be crushed, the volume of water needed to dissolve the drug, time for that process, and volume needed to rinse the tube after administration was also studied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results of this review are summarized in a table and based on a composite of the documents cited, tests conducted, and author's judgements based all the data collected. Thirty\u2010six medications were identified as inappropriate for feeding tube administration, and an additional 46 medications were identified as inappropriate for direct jejunal administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The information produced by this study will enable clinicians to make informed choices in selecting, compounding, and rinsing medications through feeding tubes. Using the template provided, they will be able to evaluate a drug not studied here for potential issues in feeding tube administration.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jpen.2490","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T09:44:25Z","timestamp":1677491065000},"page":"519-540","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Developing guidance for feeding tube administration of oral medications"],"prefix":"10.1002","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8753-9783","authenticated-orcid":false,"given":"Mark G.","family":"Klang","sequence":"first","affiliation":[{"name":"Research Pharmacy Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607116673053"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/56.15.1529"},{"key":"e_1_2_10_4_1","unstructured":"ISMP. Do not crush list.2022. Accessed August 7 2022.https:\/\/www.ismp.org\/resources\/oral-dosage-forms-should-not-be-crushed-wall-chart"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607112471560"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607183007002186"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.02.001"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-110-9-734"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2006.01.020"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph15080975"},{"key":"e_1_2_10_11_1","unstructured":"Anon. Oral drug products administered via enteral feeding tube: in vitro testing and labeling recommendations. U.S. Food and Drug Administration 2022. Accessed August 11 2022.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/oral-drug-products-administered-enteral-feeding-tube-in-vitro-testing-and-labeling-recommendations"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/001857870403900308"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080155"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.5863\/1551-6776-26.2.172"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13668-019-00290-4"},{"issue":"4","key":"e_1_2_10_16_1","first-page":"276","article-title":"Recommendations for compounding medications for feeding tube administration","volume":"14","author":"Klang M","year":"2010","journal-title":"Int J Pharm Compd"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198912000-00010"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(75)80228-9"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.4037\/ccn1994.14.1.68"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)82470-9"},{"key":"e_1_2_10_21_1","unstructured":"Anon. Ora\u2010Sweet\u00ae Paddock Laboratories. Padagis;2022. Accessed September 16 2022.https:\/\/www.stobec.com\/DATA\/PRODUIT\/1409%7Ev%7Edata_8196.pdf"},{"key":"e_1_2_10_22_1","unstructured":"Anon. \u2329795\u232a Pharmaceutical Compounding\u2014Nonsterile Preparations. United States Pharmacopeia and National Formulary (USP43\u2010NF38). United States Pharmacopeial Convention;2022."},{"key":"e_1_2_10_23_1","unstructured":"RothMD E KlangM ShellK et al. Drug\u2013nutrient interactions clinical oysters: more meat than a pearl (T41).2015."},{"key":"e_1_2_10_24_1","volume-title":"Zovirax\u00ae (Acyclovir) Package Insert","author":"Anon","year":"2003"},{"key":"e_1_2_10_25_1","first-page":"752","volume-title":"V. Handbook of Drug Administration Via Enteral Feeding Tubes","author":"White RB","year":"2015"},{"key":"e_1_2_10_26_1","unstructured":"Anon. United States Pharmacopeia and National Formulary (USP 43\u2010NF 38) 2022. Accessed August 31 2022.https:\/\/online.uspnf.com\/uspnf\/document\/1_GUID-98DCB48D-DC23-4A63-AD2E-01CA8979FB7E_5_en-US?source=Quick%20Search%26highlight=795"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.13075\/ijomeh.1896.01534"},{"key":"e_1_2_10_28_1","unstructured":"Anon.Rx\u2010Crush 2022. Accessed September 16 2022.https:\/\/www.rxcrush.com\/"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607108330314"},{"key":"e_1_2_10_30_1","first-page":"34","article-title":"Sterile water and enteral feeding: fear over logic","volume":"156","author":"Rice T","year":"2016","journal-title":"Pract Gastroenterol"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2006.00730.x"},{"key":"e_1_2_10_32_1","unstructured":"Cassodex (Bicalutamide) Package Insert.1995."},{"key":"e_1_2_10_33_1","unstructured":"Anon. Dostinex (Cabergoline) Package Insert Pharmacia & Upjohn Company NY NY.2011; (Reference ID: 2975239)."},{"key":"e_1_2_10_34_1","unstructured":"Anon. Invokana\u00ae (Canagliflozin) Package Insert Janssen Pharmaceuticals Inc. Titusville NJ.2016; (Reference ID: 3907892)."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3182940426"},{"key":"e_1_2_10_36_1","unstructured":"Anon. Plavix (Clopidogrel Bisulfate) Tablets Package Insert Bristol\u2010Myers Squibb\/Sanofi Pharmaceuticals Partnership Bridgewater NJ.1997."},{"key":"e_1_2_10_37_1","unstructured":"Anon. Declomycin (Demeclocycline Hydrochloride) Mova Pharmaceutical Corporation.2001; (80831 Rev.\u20100607)."},{"issue":"1","key":"e_1_2_10_38_1","first-page":"153","article-title":"Pharmacokinetics of enalapril and lisinopril in subjects with normal and impaired hepatic function","volume":"3","author":"Hayes PC","year":"1989","journal-title":"J Hum Hypertens"},{"key":"e_1_2_10_39_1","volume-title":"Edecrin (Ethacrynic Acid)","author":"Anon","year":"1984"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.6846"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2004.10.011"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-005-2504-z"},{"key":"e_1_2_10_43_1","unstructured":"Anon. Gleevec (Imatinib Mesylate) Package Insert Novartis Pharma Stein AG Stein Switzerland.2001."},{"key":"e_1_2_10_44_1","unstructured":"Anon. NIZORAL (Ketoconazole) Package Insert Janssen Pharmaceuticals Inc. New Jersey: Titusville;2013; (Reference ID: 3347210)."},{"key":"e_1_2_10_45_1","volume-title":"Lamictal (Lamotrigine) Package Insert","author":"Anon","year":"2009"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80043-9"},{"key":"e_1_2_10_47_1","unstructured":"Anon. Prevacid (Lansoprazole) Package Insert Takeda Pharmaceuticals America Inc.2012; (Reference ID: 3193013)."},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10837450.2021.1948567"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp090231"},{"key":"e_1_2_10_50_1","unstructured":"Anon. Lithium Carbonate Package Insert Roxane Laboratories Inc. Columbus Ohio.2011; (Reference ID: 3031563)."},{"issue":"4","key":"e_1_2_10_51_1","first-page":"257","article-title":"Bioavailability of US commercial magnesium preparations","volume":"14","author":"Firoz M","year":"2001","journal-title":"Magnes Res"},{"key":"e_1_2_10_52_1","unstructured":"SchallomM. How to recognize prevent and troubleshoot mechanical complications of enteral feeding tubes. American Nurse. Published February 3 2016. Accessed November 1 2023.https:\/\/www.myamericannurse.com\/recognize-prevent-troubleshoot-mechanical-complications-enteral-feeding-tubes\/"},{"key":"e_1_2_10_53_1","unstructured":"Anon. Cytotec (misoprostol) package insert Pfizer Inc. NY NY.2021."},{"key":"e_1_2_10_54_1","unstructured":"Anon. Viracept\u00ae (Nelfinavir Mesylate) Package Insert Agouron Pharmaceuticals Inc. La Jolla CA 2005."},{"key":"e_1_2_10_55_1","unstructured":"Anon. Aygestin\u00ae (Norethindrone Acetate Tablets) Package Insert Duramed Pharmaceuticals Inc.2007."},{"key":"e_1_2_10_56_1","unstructured":"Anon. Zyprexa (Olanzapine) Package Insert Eli Lilly and Company Indianapolis IN.2010; (Reference ID: 2870829)."},{"key":"e_1_2_10_57_1","unstructured":"Anon. Benicar (Olmesartan Medoxomil) Package Insert Daiichi Sankyo Inc. Parsippany New Jersey.2009; (Reference ID: 2956216)."},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03522.x"},{"key":"e_1_2_10_59_1","unstructured":"Anon. Zofran (Ondansetron Hydrochloride) Oral Solution Package Insert Glaxosmithkline Research Triangle Park.2016; (Reference ID: 4011596)."},{"key":"e_1_2_10_60_1","unstructured":"Anon. Tamiflu\u00ae (Oseltamivir Phosphate) for Oral Suspension) Package Insert Gilead Sciences Inc. Foster City California.2012; (Reference ID: 3235738)."},{"key":"e_1_2_10_61_1","unstructured":"Anon. Trileptal (Oxcarbazepine) Film\u2010Coated Tablet Package Insert Novartis.2017; (Reference ID: 4073998)."},{"key":"e_1_2_10_62_1","unstructured":"Anon. Noxafil\u00ae (Posaconazole) Oral Suspension 40 mg\/mL Package Insert Merck and Co Whitehouse Station NJ.2014; (Reference ID: 3847805)."},{"key":"e_1_2_10_63_1","unstructured":"Anon. Pravachol (Pravastatin Sodium) Tablets Package Insert Bristol\u2010Myers Squibb Company Princeton New Jersey.1991; (Reference ID: 3090896)."},{"key":"e_1_2_10_64_1","unstructured":"Anon. Lyrica (Pregabalin) Oral Solution Package Insert Pfizer \u2013 Parke\u2010Davis.2018; (Reference ID: 4252171)."},{"key":"e_1_2_10_65_1","unstructured":"Anon. Accupril (Quinapril Hydrochloride Tablets) Package Insert Pfizer Parke\u2010Davis NY NY.2011; (Reference ID: 3073121)."},{"key":"e_1_2_10_66_1","unstructured":"Anon. Prandin\u00ae (Repaglinide) Tablets Package Insert Gemini Laboratories LLC Bridgewater NJ.1997; (Reference ID: 4378916)."},{"key":"e_1_2_10_67_1","unstructured":"Anon. Risperdal (Risperidone) Tablets Package Insert Janssen Division of Ortho\u2010McNeil\u2010Janssen Pharmaceuticals Inc. Titusville NJ.1993."},{"key":"e_1_2_10_68_1","unstructured":"Anon. Viread (Tenofovir Disoproxil Fumarate) Tablets Package Insert Gilead Sciences Inc. Foster City CA.2012; (Reference ID: 3175615)."},{"key":"e_1_2_10_69_1","unstructured":"Anon. Lysteda (Tranexamic Acid) Tablets Package Insert Ferring Pharmaceuticals Inc. Parsippany NJ 2013; (Reference ID: 3383847)."},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1177\/0148607109337257"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(96)85200-8"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/001857870203700217"},{"key":"e_1_2_10_73_1","unstructured":"Anon. Cipro (package insert). Bayer HealthCare Pharmaceuticals Inc. Whippany NJ 07981;1997."},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/014860710002400142"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.7.1118"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1177\/105477389500400306"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu13020463"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000319958.37502.8e"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.32.5.570"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/0884533612449488"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rgmx.2012.06.003"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19355"},{"key":"e_1_2_10_83_1","unstructured":"KlangM. Dietary protein interfernce with phenytoin dissolution. Thesis Submission LIU;2008."}],"container-title":["Journal of Parenteral and Enteral Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpen.2490","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jpen.2490","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jpen.2490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T10:43:45Z","timestamp":1760870625000},"score":1,"resource":{"primary":{"URL":"https:\/\/aspenjournals.onlinelibrary.wiley.com\/doi\/10.1002\/jpen.2490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/jpen.2490"],"URL":"https:\/\/doi.org\/10.1002\/jpen.2490","archive":["Portico"],"relation":{},"ISSN":["0148-6071","1941-2444"],"issn-type":[{"value":"0148-6071","type":"print"},{"value":"1941-2444","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,22]]},"assertion":[{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}